These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies. Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082 [TBL] [Abstract][Full Text] [Related]
3. Docking applied to the prediction of the affinity of compounds to P-glycoprotein. Palestro PH; Gavernet L; Estiu GL; Bruno Blanch LE Biomed Res Int; 2014; 2014():358425. PubMed ID: 24982867 [TBL] [Abstract][Full Text] [Related]
4. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360 [TBL] [Abstract][Full Text] [Related]
5. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284 [TBL] [Abstract][Full Text] [Related]
6. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications. Zsila F Curr Drug Metab; 2007 Aug; 8(6):563-93. PubMed ID: 17691918 [TBL] [Abstract][Full Text] [Related]
7. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Crivori P; Reinach B; Pezzetta D; Poggesi I Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367 [TBL] [Abstract][Full Text] [Related]
8. A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. Singh DV; Godbole MM; Misra K J Mol Model; 2013 Jan; 19(1):227-38. PubMed ID: 22864626 [TBL] [Abstract][Full Text] [Related]
9. Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein. Teng YN; Wang CCN; Liao WC; Lan YH; Hung CC Molecules; 2020 Jan; 25(2):. PubMed ID: 31936160 [No Abstract] [Full Text] [Related]
10. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Zhou SF Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages. Zha W; Wang G; Xu W; Liu X; Wang Y; Zha BS; Shi J; Zhao Q; Gerk PM; Studer E; Hylemon PB; Pandak WM; Zhou H PLoS One; 2013; 8(1):e54349. PubMed ID: 23372711 [TBL] [Abstract][Full Text] [Related]
12. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Abraham I; Jain S; Wu CP; Khanfar MA; Kuang Y; Dai CL; Shi Z; Chen X; Fu L; Ambudkar SV; El Sayed K; Chen ZS Biochem Pharmacol; 2010 Nov; 80(10):1497-506. PubMed ID: 20696137 [TBL] [Abstract][Full Text] [Related]
13. A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking. Kadioglu O; Efferth T Cells; 2019 Oct; 8(10):. PubMed ID: 31640190 [TBL] [Abstract][Full Text] [Related]
15. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening. Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191 [TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy. Breier A; Barancík M; Sulová Z; Uhrík B Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819 [TBL] [Abstract][Full Text] [Related]
17. Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier. Emmert D; Campos CR; Ward D; Lu P; Namanja HA; Bohn K; Miller DS; Sharom FJ; Chmielewski J; Hrycyna CA ACS Chem Neurosci; 2014 Apr; 5(4):305-17. PubMed ID: 24483607 [TBL] [Abstract][Full Text] [Related]
18. In silico model for P-glycoprotein substrate prediction: insights from molecular dynamics and in vitro studies. Prajapati R; Singh U; Patil A; Khomane KS; Bagul P; Bansal AK; Sangamwar AT J Comput Aided Mol Des; 2013 Apr; 27(4):347-63. PubMed ID: 23612916 [TBL] [Abstract][Full Text] [Related]
19. Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2. Ritchie TK; Kwon H; Atkins WM J Biol Chem; 2011 Nov; 286(45):39489-96. PubMed ID: 21937435 [TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Pleban K; Kopp S; Csaszar E; Peer M; Hrebicek T; Rizzi A; Ecker GF; Chiba P Mol Pharmacol; 2005 Feb; 67(2):365-74. PubMed ID: 15509712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]